Yes, BRCA1 and BRCA2 mutations follow an autosomal dominant inheritance pattern. This means the mutation sits on a non-sex chromosome, and inheriting just one copy from either parent is enough to pass along the increased cancer risk. Each child of a carrier has a 50% chance of inheriting the mutation.
What Autosomal Dominant Means for BRCA
“Autosomal” tells you the gene is on one of the 22 numbered chromosomes, not on the X or Y chromosome. That matters because it means sons and daughters inherit the mutation at equal rates. A father can pass a BRCA mutation to his children just as readily as a mother can.
“Dominant” refers to how the cancer risk is inherited, not how cancer itself develops. You only need one altered copy of BRCA1 or BRCA2 to carry a significantly elevated lifetime risk of certain cancers. You don’t need to inherit a faulty copy from both parents. This is what makes the inheritance pattern dominant: a single copy changes your medical outlook.
Why One Mutation Doesn’t Guarantee Cancer
This is where BRCA genetics gets nuanced. The inheritance of cancer risk is dominant, but cancer itself requires a second event at the cellular level. BRCA1 and BRCA2 are tumor suppressor genes. Their job is to help repair damaged DNA. When both copies of the gene stop working inside a cell, that cell loses a critical safety mechanism and can grow uncontrollably.
People born with one mutated copy still have one working copy in every cell. Cancer develops only if that second, working copy gets knocked out by a random mutation sometime during a person’s life. This concept, known as the “two-hit” model, explains why carriers face a high but not 100% lifetime risk. The first “hit” is inherited. The second happens by chance in a specific tissue, like breast or ovarian cells. Some carriers never experience that second hit and never develop cancer.
How High the Cancer Risk Actually Is
More than 60% of women who inherit a harmful BRCA1 or BRCA2 change will develop breast cancer during their lifetime, compared to roughly 13% of women in the general population. The risk for ovarian cancer is also substantially elevated, particularly with BRCA1 mutations.
Men who carry BRCA mutations face increased risks too, including higher rates of prostate cancer and male breast cancer. BRCA2 carriers are estimated to have two to five times the prostate cancer risk of men in the general population. Because the inheritance is autosomal, not sex-linked, men are just as likely as women to carry and pass on the mutation, even if their own cancer risks manifest differently.
The 50/50 Chance in Every Pregnancy
Each pregnancy is an independent event. If one parent carries a BRCA mutation, every child has a 50% chance of inheriting it, regardless of whether older siblings did or didn’t. Two siblings in the same family can have completely different results. This is why genetic testing of individual family members matters so much, rather than assuming shared status based on one person’s result.
The mutation can also skip apparent generations in terms of visible cancer. A father might carry BRCA2, never develop cancer himself, and pass it to a daughter who does. Looking at a family tree, it might seem like the mutation “came from nowhere,” when it was actually present but silent in the generation between.
Cascade Testing in Families
Once a pathogenic BRCA variant is found in one family member, the recommended next step is cascade testing: systematically offering genetic testing to blood relatives. This is simpler and cheaper than broad genetic screening because the lab already knows the exact mutation to look for. A relative either has that specific change or they don’t.
If the test comes back negative, that person’s cancer risk drops back to the baseline for the general population. If positive, they qualify for enhanced screening (such as breast MRI starting at a younger age) and can consider risk-reducing options. Bilateral preventive mastectomy, for example, reduces breast cancer risk by at least 95% in BRCA carriers. Preventive removal of the ovaries and fallopian tubes also significantly lowers ovarian cancer risk. These are personal decisions, but they become available only when carrier status is known.
When Test Results Are Unclear
Not every BRCA test result is a clean positive or negative. Genetic testing labs classify variants into five categories: pathogenic, likely pathogenic, uncertain significance (VUS), likely benign, and benign. A VUS result means the lab found a genetic change but doesn’t yet have enough evidence to say whether it’s harmful.
This uncertainty is genuinely difficult for patients. Carriers of a VUS can’t qualify for the same clinical management strategies available to people with confirmed pathogenic variants, like enhanced screening protocols or preventive surgery based on that result alone. The good news is that reclassification research is ongoing and effective. In one study of BRCA2 variants of uncertain significance, functional testing allowed 92.5% of them to be reclassified as either likely benign or likely pathogenic. If you receive a VUS result, your genetic counselor will typically recommend periodic check-ins, since the classification may change as more data accumulates.
Who Should Consider Testing
Guidelines from major oncology organizations recommend genetic counseling and testing for people with specific risk factors: a strong family history of breast or ovarian cancer, cancer diagnosed at an unusually young age, multiple cancers in the same person, male breast cancer in the family, or known BRCA mutations in a relative. Ashkenazi Jewish ancestry is another recognized risk factor, as BRCA1 mutations occur at roughly twice the rate seen in other populations.
Testing typically starts with the family member most likely to carry the mutation, often someone who has already been diagnosed with cancer. Their result then guides whether cascade testing is offered to relatives. If you’re considering testing without a known family mutation, a genetic counselor can help you assess whether your personal and family history meets current criteria.